COMPULSORY LICENSING OF PATENTS: A CASE STUDY OF THE INDIAN PHARMACEUTICAL INDUSTRY BY: SAKSHAM GUPTA

SAKSHAM GUPTA

Published Paper

Article Details

COMPULSORY LICENSING OF PATENTS: A CASE STUDY OF THE INDIAN PHARMACEUTICAL INDUSTRY

AUTHORED BY: SAKSHAM GUPTA

Abstract

Compulsory licensing is an essential legal mechanism allowing governments to grant permission to manufacture patented products without the patent holder's consent under specific conditions. In India, compulsory licensing has played a crucial role in ensuring access to affordable medicines. This paper explores the concept of compulsory licensing, its legal framework in India, notable case studies, challenges, and implications for the pharmaceutical industry. It further examines the balance between public health and patent rights through judicial pronouncements and international legal frameworks. Compulsory licensing of patents is a crucial mechanism in intellectual property law that seeks to balance patent rights with public health and economic considerations. In the pharmaceutical industry, where patented drugs are often prohibitively expensive, compulsory licensing ensures wider accessibility to essential medicines, particularly in developing nations like India. The Indian legal framework, governed by the Patents Act, 1970 (as amended in 2005), provides specific provisions under Sections 84, 92, and 100, allowing for compulsory licensing in cases of non-availability, exorbitant pricing, or national emergencies.

This paper critically examines the implementation of compulsory licensing in India, focusing on its legal foundations, landmark case laws, and broader implications for the pharmaceutical industry. The Natco Pharma Ltd. v. Bayer Corporation (2012) case, which granted India’s first compulsory license for the cancer drug Sorafenib Tosylate (Nexavar), is analyzed in detail to illustrate how affordability and accessibility concerns influence legal decisions. Additionally, cases such as Lee Pharma v. AstraZeneca (2015) and BDR Pharmaceuticals v. Bristol-Myers Squibb (2013) highlight the stringent criteria for granting compulsory licenses and the procedural challenges faced by applicants. While compulsory licensing has been instrumental in promoting generic drug manufacturing and ensuring affordable healthcare, it also faces significant challenges. Pharmaceutical companies argue that it discourages innovation, reduces incentives for research and development (R&D), and raises concerns over compliance with international trade agreements, particularly the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the Doha Declaration on Public Health. Furthermore, the procedural requirements for obtaining a compulsory license, including prior negotiation attempts and proof of public necessity, often lead to lengthy legal battles.

The paper also explores the broader economic and international policy implications of India’s compulsory licensing regime, particularly its impact on global pharmaceutical trade relations and access to life-saving drugs in low-income countries. Policy recommendations are proposed to enhance the effectiveness of compulsory licensing, including clarifying legal criteria, improving international cooperation, fostering domestic pharmaceutical capacity, and encouraging voluntary licensing agreements as an alternative.

Through a critical analysis of legal provisions, case studies, and policy perspectives, this paper underscores the need for a balanced approach that safeguards public health while maintaining a robust innovation ecosystem. It concludes that while compulsory licensing remains a powerful tool for ensuring drug affordability, its implementation must be refined to address both legal complexities and global pharmaceutical industry concerns.

Keywords

Compulsory licensing, patents, pharmaceutical industry, TRIPS Agreement, public health, patent law, India, intellectual property rights, compulsory licensing, patents, pharmaceutical industry, public health, Indian patent law, generic drugs, affordability, Doha Declaration.

Introduction

Patents grant exclusive rights to inventors, encouraging innovation and investment in research and development. However, they also create monopolies that may hinder access to essential medicines. Compulsory licensing serves as a safeguard to balance patent rights with public health needs, particularly in developing countries like India, where affordability of medicines remains a critical concern.

This paper provides an in-depth analysis of compulsory licensing in India[1], focusing on the legal provisions under the Indian Patent Act, 1970, case law developments, and its impact on the pharmaceutical industry. The pharmaceutical industry plays a critical role in public health by developing life-saving drugs, but the high cost of patented medicines often makes them inaccessible to large sections of the population, particularly in developing countries like India. Compulsory licensing (CL) is a legal mechanism that allows a government to grant permission to a third party to manufacture a patented product without the consent of the patent holder, ensuring that essential drugs remain affordable and available to the public. This provision seeks to balance the monopoly rights of patent holders with the need to promote public welfare, especially in cases where the patented drug is unaffordable or insufficiently supplied.

Patents are granted to incentivize innovation by providing exclusive rights to inventors for a limited period, typically 20 years from the date of filing. However, when patents prevent access to essential medicines due to high costs or inadequate supply, compulsory licensing serves as a safeguard against market exclusivity abuses. Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), adopted by the World Trade Organization (WTO), provides member states with the flexibility to issue CL under certain conditions. The Doha Declaration[2] on Public Health (2001) further reinforced this right, stating that public health concerns should take precedence over patent rights in cases of national emergencies, epidemics, or other extreme situations. India, being a developing country with a strong generic pharmaceutical sector, has actively used compulsory licensing to ensure access to medicines. The country amended its Patents Act, 1970, in 2005 to comply with TRIPS while incorporating Sections 84, 92, and 100, which allow for compulsory licensing under specific conditions. The first compulsory license in India was granted in 2012 to Natco Pharma[3] for the production of Bayer’s cancer drug Nexavar (Sorafenib Tosylate), marking a significant moment in Indian patent law and setting a precedent for future CL applications.

Legal Framework of Compulsory Licensing in India The Patents Act, 1970

(as Amended in 2005)

India’s compulsory licensing regime is primarily governed by the Patents Act, 1970, which was amended in 2005 to comply with the WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). These amendments introduced a product patent regime, extending patent protection to pharmaceuticals and agrochemicals while incorporating safeguards like compulsory licensing to balance patent rights with public health needs.

The key provisions on compulsory licensing in the Patents Act are as follows: Section 84: Compulsory Licensing by Application Under Section 84, any interested person (including a generic drug manufacturer) can apply for a compulsory license three years after the grant of a patent if one or more of the following conditions are met:

Non-affordability – The patented product is not reasonably affordable to the public.

1. Non-availability – The patented product is not available in sufficient quantity to meet demand.

2. Non-working of the patent in India – The patent holder has not manufactured the patented product in India or has failed to license it to local manufacturers.

Landmark Case: Natco Pharma Ltd. v. Bayer Corporation (2012)

• In 2012, Natco Pharma became the first company in India to be granted a compulsory license under Section 84 for Bayer’s anti-cancer drug, Nexavar (Sorafenib Tosylate).

• Bayer had been selling Nexavar at ?2.8 lakhs ($3,600) per month, making it unaffordable to most patients.

• Natco proposed selling the generic version at ?8,800 ($110) per month, significantly

reducing the cost.

• The Controller General of Patents ruled in Natco’s favor, stating that Bayer failed to make the drug adequately available at an affordable price and had not manufactured it in India.

• This case set a precedent for future compulsory licensing applications in India.

Section 92: Compulsory Licensing in Cases of National Emergency or Public Interest

Section 92 empowers the Central Government to issue a compulsory license suo motu (on its own) in cases of:

1. National Emergency

2. Extreme Urgency

3. Public Non-Commercial Use Implications of Section 92:

• This provision is crucial in times of pandemics, epidemics, or public health crises.

• The government does not require prior negotiation with the patent holder before issuing a compulsory license.

• During the COVID-19 pandemic, there were discussions about invoking Section 92 for licensing vaccines and essential drugs like Remdesivir and Tocilizumab, but no compulsory licenses were granted.

Case Reference: HIV/AIDS Drugs in India

• In 2001, India, Brazil, and South Africa advocated for the use of compulsory licensing to combat the HIV/AIDS crisis, leading to the Doha Declaration on TRIPS and Public Health (2001), which reaffirmed the right of nations to issue compulsory licenses for public health emergencies.

Section 100: Government Use of Patented Inventions

Section 100 permits the Indian government or any designated entity to use a patented invention for public purposes without the patent holder’s consent.

• Unlike Section 84, this provision does not require a formal application.

• The government can authorize third parties (e.g., generic drug manufacturers) to manufacture patented drugs without the patent owner’s approval.

• The patent holder is entitled to compensation, but the terms are determined by the government.

Case Reference: COVID-19 Pandemic

• During COVID-19, experts suggested that the government use Section 100 to license vaccines and drugs like Remdesivir, Favipiravir, and Molnupiravir to ensure adequate supply.

• Although Section 100 was not formally invoked, it remains a critical legal tool for future public health crises.

TRIPS Agreement and Doha Declaration

The TRIPS Agreement (1994) is a key international legal framework under the World Trade Organization (WTO) that sets minimum standards for intellectual property (IP) protection across member countries. It aims to harmonise global IP laws, encourage innovation, facilitate international trade, and prevent the misuse of IP rights. However, its patent provisions (Article 27, 31, and 31(b)) raised concerns in the pharmaceutical sector[4], as they granted exclusive rights for at least 20 years, limiting the production of affordable generic medicines. This resulted in higher prices for essential drugs, particularly affecting developing nations battling HIV/AIDS, tuberculosis, and malaria. To address these public health concerns, the Doha Declaration (2001) reaffirmed the flexibilities available under TRIPS to protect public health and promote access to medicines. It clarified that WTO members could override patents in cases of national emergencies and could freely grant compulsory licenses under Article 31 of TRIPS. It also introduced parallel importation, allowing countries to import cheaper generic versions of patented drugs, and provided special provisions for Least Developed Countries (LDCs) by extending their transition period for enforcing pharmaceutical patents until 2033. Additionally, the Paragraph 6 Mechanism[5] (later incorporated as Article 31bis) permitted nations with insufficient pharmaceutical manufacturing capacity to import generic medicines from other countries under a compulsory license. The Doha Declaration significantly impacted global public health policies, enabling developing nations to use compulsory licensing more effectively. A landmark example is India’s Natco Pharma v. Bayer case (2012), where India granted a compulsory license for Nexavar, a life-saving cancer drug, making it affordable for patients. Similarly, pharmaceutical companies adapted to these changes by implementing differential pricing strategies in developing markets.

In response to TRIPS, India amended its Patents Act in 2005 to align with the agreement while ensuring public health safeguards. The Act incorporates compulsory licensing provisions (Sections 84, 92, and 100), allowing the production of affordable medicines when patent holders fail to meet public demand. India’s robust generic pharmaceutical industry has made it a global leader in affordable drug production, supplying medicines worldwide. Key legal disputes, such as Novartis v. Union of India (2013), further reinforced India’s stance on balancing patent rights with public health needs.

Case Studies of Compulsory Licensing in India Natco Pharma Ltd. v. Bayer Corporation (2012)

Facts:

The case of Natco Pharma Ltd. v. Bayer Corporation (2012) was a landmark judgment in Indian patent law, as it was the first-ever compulsory license granted in India under Section 84 of the Patents Act, 1970 (as amended in 2005). The case revolved around the high pricing and limited accessibility of a life-saving cancer drug, Sorafenib Tosylate (marketed as Nexavar), patented by Bayer Corporation, a German pharmaceutical company.

Bayer held the exclusive patent rights for Nexavar, which was used to treat advanced-stage kidney and liver cancer. However, the drug was priced at INR 2.8 lakh (approximately $3,500) per month, making it unaffordable for most Indian patients, where the average annual income was significantly lower. Bayer had also not made efforts to manufacture the drug in adequate quantity within India, further restricting access to the medicine.

Natco Pharma, an Indian generic pharmaceutical company, applied for a compulsory license under Section 84 of the Patents Act, 1970, citing the following reasons:

1. Non-affordability – The exorbitant price of Nexavar made it inaccessible to a majority of cancer patients.

2. Non-availability in adequate quantity – Bayer was not producing the drug in sufficient quantities to meet public demand.

3. Non-working of the patent in India – Bayer imported the drug instead of manufacturing it domestically, violating India's patent "working requirement."

Judgment:

The Controller General of Patents, Designs & Trademarks ruled in favor of Natco Pharma, granting the first compulsory license under Section 84 of the Patents Act, 1970. The key aspects of the ruling were:

4. Price Reduction – Natco was allowed to manufacture and sell Nexavar at a much lower price of INR 8,800 per month, making it 97% cheaper than Bayer’s price.

5. Royalty to Bayer – Natco was required to pay a 6% royalty on net sales of the drug to Bayer as compensation for using the patent.

6. Non-Exclusive License – The compulsory license was non-exclusive, meaning other manufacturers could also apply for similar licenses.

7. Domestic Availability – Natco was required to supply the drug in sufficient quantity to meet public demand in India.

Bayer appealed the decision to the Intellectual Property Appellate Board (IPAB), but the IPAB upheld the ruling. Bayer then challenged the decision before the Bombay High Court, which also dismissed the appeal, confirming the grant of the compulsory license to Natco.

Impact:

The Natco Pharma v. Bayer case set a major precedent in Indian patent law and had a significant global impact on intellectual property rights and public health policies.

8. Reinforced Public Health Over Patent Rights – The case reaffirmed India’s commitment to ensuring that life-saving medicines remain accessible and affordable.

9. Encouraged the Use of Compulsory Licensing – The ruling legitimised the use of compulsory licensing as a legal tool to address unaffordable drug pricing.

10. Global Pharmaceutical Industry Response – The case faced criticism from multinational pharmaceutical companies, arguing that it could discourage foreign investment in India’s pharmaceutical sector.

11. Influence on Other Countries – The case set an example for other developing nations, encouraging them to invoke compulsory licenses to make essential medicines more affordable.

12. Strengthened India’s Position as a Generic Drug Supplier – By allowing compulsory licensing, India continued to maintain its status as the “pharmacy of the developing world”, producing affordable generic medicines for global markets.

Lee Pharma v. AstraZeneca (2015)

Facts:

The case of Lee Pharma v. AstraZeneca (2015) was a significant patent law decision in India that dealt with compulsory licensing under Section 84 of the Patents Act, 1970. This case highlighted the stringent conditions that an applicant must meet to obtain a compulsory license and reinforced the fact that merely alleging high drug prices or non-working of a patent is not sufficient for a compulsory license to be granted.

The dispute arose over the diabetes drug Saxagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, patented by AstraZeneca, a British-Swedish multinational pharmaceutical company. Saxagliptin was used to treat Type-2 diabetes mellitus and was sold under the brand name Onglyza.

Lee Pharma, an Indian generic drug manufacturer, applied for a compulsory license to manufacture and sell a generic version of Saxagliptin in India. The company filed its application under Section 84 of the Patents Act, 1970, arguing that AstraZeneca had not worked the patent in India adequately and that the drug was not reasonably affordable to the public.

Judgment:

The Controller General of Patents rejected Lee Pharma’s application for a compulsory license, ruling that the company had not provided sufficient evidence to satisfy the three conditions under Section 84(1).

The key points in the ruling were:

1. Affordability Not Proven – The Controller held that Lee Pharma had failed to prove that Saxagliptin was unaffordable for the general public. Unlike in Natco Pharma v. Bayer (2012), where the cancer drug Nexavar was exorbitantly priced (INR 2.8 lakh per month), Saxagliptin was reasonably priced in comparison to similar diabetes medications available in India.

2. Adequate Supply Established – AstraZeneca was importing the drug and ensuring its availability through its local distributors. Therefore, the argument of inadequate supply was not supported by sufficient evidence.

3. Patent Working Not Limited to Local Manufacturing – The Controller reaffirmed that "working a patent" does not necessarily require local manufacturing. If a patent holder ensures the drug's availability in India through imports, it can still be considered as “worked” in the country.

4. Failure to Demonstrate Public Interest – The application did not establish that granting a compulsory license would serve the public interest, especially when other diabetes medications were available in India.

Since none of the three conditions under Section 84(1) were satisfied, Lee Pharma’s application for a compulsory license was rejected.

Impact:

The Lee Pharma v. AstraZeneca (2015) case reinforced the high threshold for granting compulsory licenses under Indian patent law. Unlike in Natco Pharma v. Bayer (2012), where the patented cancer drug was excessively priced and unavailable to the public, the Controller found that Saxagliptin was sufficiently available and reasonably priced.

5. Strict Standards for Compulsory Licensing – The case highlighted that a compulsory license would only be granted if all three conditions of Section 84(1) were strictly met.

6. Clarification on Patent Working Requirement – The ruling reaffirmed that importing a drug can satisfy the "working" requirement, contradicting claims that local manufacturing is mandatory for patent holders.

7. Distinction from the Natco Pharma v. Bayer Case – The case demonstrated that each application for a compulsory license is judged on its merits, and not every high-priced drug automatically qualifies for compulsory licensing.

8. Encouraged Research-Based Pharma Companies – The rejection of the license reassured multinational pharmaceutical companies that compulsory licenses in India would not be granted arbitrarily.

BDR Pharmaceuticals v. Bristol-Myers Squibb (2013)

Facts:

The case of BDR Pharmaceuticals v. Bristol-Myers Squibb (2013) revolved around a compulsory licensing application for the leukemia drug Dasatinib, a BCR-ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML).

Bristol-Myers Squibb (BMS), a multinational pharmaceutical company, held the patent for Dasatinib in India, which was marketed under the brand name Sprycel. BDR Pharmaceuticals, an Indian generic drug manufacturer, sought a compulsory license under Section 84 of the Patents Act, 1970, to manufacture and sell a cheaper version of the drug.

BDR’s key arguments for seeking a compulsory license were:

1. Unaffordability of Dasatinib – BMS was selling the drug at a very high price, making it inaccessible to a majority of leukemia patients in India.

2. Inadequate Supply – BDR alleged that the patent holder was not making the drug available in sufficient quantities to meet patient demand.

3. Non-working of the Patent in India – The company claimed that BMS was not manufacturing Dasatinib in India, which justified granting a compulsory license.

However, unlike in Natco Pharma v. Bayer (2012), where a compulsory license was granted, the BDR application was denied on procedural grounds.

Impact:

The BDR Pharmaceuticals v. Bristol-Myers Squibb (2013) case reinforced the strict procedural requirements for seeking a compulsory license under Indian patent law. The key takeaways were:

1. Mandatory Prior Negotiation for a Voluntary License

? This case clarified the importance of genuine efforts to obtain a voluntary license before seeking a compulsory license.

? Applicants cannot simply send a formal request and immediately approach the patent office—they must actively negotiate with the patent holder.

2. Strict Interpretation of the Six-Month Waiting Period

? The case emphasized that the six-month negotiation period under Section 84(6) must be strictly adhered to.

? Premature applications will be rejected without consideration of affordability or public interest.

3. Different Outcome Compared to Natco Pharma v. Bayer (2012)

? Unlike in the Natco case, where there was clear evidence of high pricing and limited access, BDR failed to provide strong evidence that Dasatinib was unaffordable or unavailable.

? This case demonstrated that each compulsory license application is judged on its

own facts, and a prior grant of a compulsory license does not set an automatic precedent.

4. Encouraged Patent Holders to Engage in Fair Licensing Practices

? The ruling reassured innovator pharmaceutical companies that India would not arbitrarily grant compulsory licenses without following due process.

? However, it also signaled to patent holders that they must engage in fair negotiations if approached for voluntary licenses.

Challenges and Criticism of Compulsory Licensing

Compulsory licensing in the pharmaceutical sector remains a highly debated issue, with concerns raised by both industry stakeholders and legal experts. While it plays a crucial role in ensuring access to essential medicines, it also presents significant challenges. These challenges can be broadly categorized into pharmaceutical industry concerns and legal and procedural barriers.

Pharmaceutical Industry Concerns

Threat to Innovation and Research & Development (R&D)

One of the primary concerns raised by multinational pharmaceutical companies and research-driven organizations is that compulsory licensing reduces incentives for innovation. Developing a new drug involves extensive research, clinical trials, and regulatory approvals, often requiring billions of dollars in investment. Companies expect to recoup these costs through patent exclusivity, which allows them to set prices based on market demand. However, when governments issue compulsory licenses, patent holders lose their exclusive rights, and generic manufacturers can produce and sell the drug at a lower price.

Critics argue that if compulsory licensing is frequently invoked, pharmaceutical firms might be discouraged from investing in high-risk drug discovery. This could particularly impact research in neglected diseases, rare diseases, and novel treatments, where financial returns are already uncertain[6]. While public health remains a priority, excessive reliance on compulsory licenses could inadvertently slow down drug innovation, leaving fewer treatment options for future diseases.

Impact on Foreign Investment and Market Confidence

Pharmaceutical companies often consider patent protection and regulatory certainty before investing in a country. Countries with strong intellectual property (IP) protection laws attract higher levels of foreign direct investment (FDI) in the pharmaceutical sector, as companies are assured that their intellectual property will be safeguarded.

India’s issuance of compulsory licenses, particularly in the case of Natco Pharma v. Bayer (2012), has drawn criticism from global investors. Some multinational corporations (MNCs) have expressed reluctance to expand their presence in India, fearing that their patented drugs may be subject to compulsory licensing. This could limit the availability of cutting-edge medicines in the Indian market, as companies may delay launching new drugs to avoid potential compulsory licensing threats.

Additionally, companies that invest heavily in clinical trials and local drug development expect strong patent protection as a return on investment. If compulsory licenses become a frequent measure, there is a risk that global pharmaceutical firms may shift their focus to other markets with stronger patent protections, impacting India’s competitiveness in the pharmaceutical sector.

International Trade Disputes and Political Backlash

The use of compulsory licensing in India has led to diplomatic and trade tensions with countries such as the United States and the European Union. Developed nations, particularly the U.S. Trade Representative (USTR), have repeatedly criticized India’s IP policies in their annual Special 301 Report, which monitors intellectual property enforcement across countries.

In the past, India’s granting of a compulsory license to Natco for Bayer’s cancer drug (Nexavar) and legal battles involving Novartis, Roche, and Bristol-Myers Squibb have been raised as trade concerns by Western pharmaceutical lobbies. The U.S. and EU have argued that India’s approach to compulsory licensing acts as a barrier to free trade and undermines international IP standards under the TRIPS Agreement.

There have been instances where Western governments and pharmaceutical industry groups have lobbied for stricter trade sanctions against India, citing its compulsory licensing policies as an unfair trade practice. This has led to political pressure on India to align its patent laws more closely with international IP regimes, raising questions about the balance between public health and global trade obligations.

Legal and Procedural Barriers

Stringent Requirements for Obtaining a Compulsory License

While India’s compulsory licensing provisions under the Patents Act, 1970 (Section 84) offer flexibility, the burden of proof on an applicant seeking a compulsory license is exceptionally high. Before a compulsory license is granted, the applicant must demonstrate that:

• The patented drug is not reasonably affordable to the public.

• The drug is not available in adequate quantities to meet the demand.

• The patent holder has not worked the invention in India (i.e., has not manufactured or supplied the drug sufficiently).

These requirements are strictly interpreted, making it challenging for generic manufacturers to qualify for a compulsory license. For example, in the case of Lee Pharma v. AstraZeneca (2015), the application was rejected because Lee Pharma failed to provide strong evidence that AstraZeneca had neglected to make the drug available or that the drug was unaffordable to the Indian public.

Additionally, the requirement to negotiate for a voluntary license before applying for a compulsory license (as seen in BDR Pharmaceuticals v. Bristol-Myers Squibb, 2013) adds another procedural hurdle. If the patent holder refuses to negotiate, the process becomes prolonged and uncertain, discouraging applicants from pursuing compulsory licenses.

Litigation Delays and Legal Challenges by Patent Holders

Even when a compulsory license is granted, patent holders often challenge the decision in court, leading to lengthy legal battles. Large pharmaceutical companies possess significant financial and legal resources, allowing them to engage in prolonged litigation to delay the implementation of compulsory licenses.

For instance, in Natco Pharma v. Bayer (2012), Bayer filed multiple appeals challenging the decision, first before the Intellectual Property Appellate Board (IPAB) and later before the Bombay High Court. Although the compulsory license was ultimately upheld, the legal delays prevented immediate access to the generic version of Nexavar for patients in need.

Such litigation tactics increase costs and uncertainties for generic manufacturers, who may be discouraged from pursuing compulsory licenses due to the fear of being entangled in years of legal proceedings. The delay in implementing compulsory licenses effectively negates their purpose, as patients may continue to lack access to affordable medicines while legal disputes drag on.

Lack of Clarity in Implementation and Statutory Ambiguities

Another challenge in India’s compulsory licensing framework is the lack of clear guidelines on implementation. While the Patents Act provides a legal basis for compulsory licensing, there are no specific mechanisms detailing how government agencies should enforce and monitor compliance.

For instance, after granting a compulsory license, who ensures that the generic version is produced efficiently, distributed fairly, and priced affordably? What mechanisms exist to prevent generic manufacturers from exploiting the system or producing substandard drugs? These questions remain unanswered in the current legal framework.

Moreover, ambiguities in the statutory provisions often create confusion in judicial interpretation. Different cases have seen varying interpretations of affordability, working of the patent, and availability of the drug, leading to inconsistent precedents. The lack of well-defined standards makes it difficult for applicants to assess their chances of obtaining a compulsory license, further discouraging them from applying.

The Way Forward: Policy Recommendations

India's compulsory licensing regime has played a crucial role in ensuring affordable access to essential medicines, especially for life-threatening diseases like cancer and HIV/AIDS. However, the framework has also faced challenges from pharmaceutical companies, trade partners, and procedural barriers. Moving forward, a balanced approach is needed—one that safeguards public health interests while preserving incentives for pharmaceutical innovation. Below are some key policy recommendations to strengthen India's compulsory licensing system and address existing concerns.

Strengthening Public Health Safeguards[7]

The primary objective of compulsory licensing should be to prioritize public health over patent monopolies. To achieve this, the Indian government should take a proactive approach by:

• Issuing compulsory licenses for life-threatening diseases: Currently, compulsory licensing is issued only after an application is made by a third party, which delays access to medicines. The government should have the power to directly issue licenses in cases where the public health burden is severe.

• Expanding the scope of national emergencies: Section 92 of the Patents Act allows the government to issue compulsory licenses during a national emergency or extreme urgency. The government should broaden the definition to include non-epidemic but critical diseases, such as rare cancers, genetic disorders, and antimicrobial resistance (AMR).

• Creating a fast-track approval process: The current process for granting compulsory licenses is time-consuming, as seen in cases like Natco Pharma v. Bayer (2012) and BDR Pharma v. Bristol-Myers Squibb (2013). A fast-track mechanism should be introduced for drugs treating life-threatening conditions, ensuring that generic alternatives reach patients sooner.

By strengthening these public health safeguards, India can ensure that compulsory licensing remains an effective tool to combat health crises and ensure drug accessibility.

Encouraging Local Manufacturing of Generic Drugs[8]

One of the primary reasons for granting compulsory licenses is to ensure that essential medicines are available in adequate quantities. However, India's domestic pharmaceutical industry must be better equipped to meet these demands. Key steps to achieve this include:

• Providing financial and policy incentives: The government should offer tax benefits, subsidies, and low-interest loans to domestic pharmaceutical firms to boost generic drug production.

• Strengthening API (Active Pharmaceutical Ingredient) manufacturing: India remains highly dependent on China for the supply of APIs, which are essential for drug manufacturing. To reduce reliance on imports, India should invest in domestic API production and develop self- sufficiency in the supply chain.

• Developing public-private partnerships (PPPs): The government can collaborate with private pharmaceutical firms to enhance research, production capacity, and distribution of generic medicines under compulsory licensing.

• Encouraging R&D in generic drug development: Even though generic drugs are copies of patented medicines, process innovations can improve their effectiveness and affordability. The government should support research on cost-effective drug synthesis methods to boost the competitiveness of Indian generics in global markets.

By incentivizing local pharmaceutical firms, India can increase its production of affordable medicines and reduce dependency on foreign pharmaceutical giants, reinforcing its global reputation as the "pharmacy of the developing world".

Strengthening International Collaboration[9]

India's compulsory licensing policies have often been challenged by multinational pharmaceutical companies and developed nations in trade disputes. Engaging with global organizations can help India defend its position and gain international legitimacy. Strategies include:

• Engaging with the World Health Organization (WHO): India should actively work with the WHO to promote the importance of compulsory licensing for public health. By aligning with WHO’s policies, India can strengthen its global credibility and counter international criticism.

• Using WTO’s TRIPS flexibilities: The Doha Declaration on TRIPS and Public Health (2001) reaffirms that public health concerns take precedence over patent rights. India should continue advocating for expanding TRIPS flexibilities to make medicines more affordable globally.

• Collaborating with other developing nations: Many countries, including Brazil, South Africa, and Thailand, face similar challenges in accessing essential medicines. India should lead a coalition of developing nations to promote fairer patent rules and resist pressure from Western pharmaceutical lobbies.

• Negotiating trade agreements with compulsory licensing provisions: India should negotiate bilateral and regional trade agreements that explicitly protect the right to issue compulsory licenses in public health emergencies. This would prevent future trade disputes and ensure long-term stability.

By engaging with international bodies and building alliances with other nations, India can strengthen its position on compulsory licensing and ensure that public health remains a priority in global trade negotiations.

Establishing a Transparent Licensing Framework[10]

One of the major criticisms of India's compulsory licensing regime is the lack of procedural clarity in the licensing process. Clearer guidelines and regulations would improve transparency, reduce legal disputes, and encourage fairer implementation. Recommendations include:

• Issuing detailed guidelines on eligibility criteria: Currently, the criteria for proving that a drug is "not reasonably affordable" or "not sufficiently worked in India" are ambiguous. The government should provide quantifiable thresholds, such as pricing benchmarks, production targets, and accessibility indicators.

• Creating an independent compulsory licensing authority: A specialized Compulsory Licensing Review Board should be established to expedite decision-making and reduce legal disputes. This would prevent delays caused by patent holder challenges and improve efficiency.

• Ensuring greater public participation: Civil society organizations, consumer rights groups, and healthcare experts should have a formal role in the decision-making process to ensure that licensing decisions are made in the best interest of public health.

• Establishing a post-license monitoring system: After a compulsory license is granted, there should be strict monitoring to ensure that the generic drug is being produced, priced, and distributed fairly. The government should set up a compliance mechanism to track sales, affordability, and accessibility.

A more transparent and structured licensing framework would increase confidence in the system, reduce legal disputes, and ensure that compulsory licenses are granted in a fair and efficient manner.

Balancing Innovation and Public Interest

While compulsory licensing is essential for public health, it should not completely undermine innovation in the pharmaceutical sector. A balanced approach that incentivizes both patent holders and generic drug manufacturers can be adopted through mechanisms such as:

• Tiered pricing models: Pharmaceutical companies can be encouraged to offer differential pricing based on a country’s economic status. For example, drugs could be sold at lower prices in low-income countries while maintaining higher prices in wealthier nations. This would reduce the need for compulsory licensing and ensure affordable access without harming innovation.

• Encouraging voluntary licensing agreements: Instead of waiting for a compulsory license, patent holders could be encouraged to enter voluntary agreements with generic manufacturers. Programs like the Medicines Patent Pool (MPP) facilitate patent-sharing agreements, ensuring affordability without legal disputes.

• Expanding government-led R&D funding: The government can directly invest in pharmaceutical R&D to reduce reliance on private companies. By funding drug development, India can promote affordable innovation while ensuring public health priorities remain at the forefront.

• Developing a compulsory licensing compensation fund: Pharmaceutical companies often argue that compulsory licenses deprive them of fair compensation. A government- administered compensation fund could partially reimburse patent holders based on generic sales revenue, ensuring a more balanced approach.

A fair and structured approach will ensure that public health needs are met while still maintaining India’s attractiveness as a hub for pharmaceutical innovation.

Conclusion

This research paper has thoroughly examined the critical role of compulsory licensing in India's pharmaceutical sector, demonstrating that it is much more than a mere legal provision—it is a strategic tool that enables the state to balance the exclusive rights granted by patents with the imperative of ensuring public access to affordable, life-saving medicines. Through a detailed analysis of the legal framework provided by the Patents Act, 1970 (as amended in 2005), and by contextualizing these provisions within international agreements such as the TRIPS Agreement and the Doha Declaration on TRIPS and Public Health (2001), the paper has shown that compulsory licensing is embedded within a broader policy objective: to prevent the monopolization of essential pharmaceuticals and thereby safeguard public health.

The landmark case of Natco Pharma Ltd. v. Bayer Corporation (2012) serves as a poignant example of the transformative impact that compulsory licensing can have. In this case, the grant of a compulsory license for Bayer’s patented cancer drug, Nexavar, was instrumental in reducing the exorbitant price from INR 2.8 lakh per month to a fraction of that cost—making the drug accessible to a much larger segment of the population. This case not only set a precedent for future licensing actions in India but also underscored the state's willingness to intervene when public health is at risk due to unaffordable patented medicines.

In contrast, the decisions in Lee Pharma v. AstraZeneca (2015) and BDR Pharmaceuticals v. Bristol-Myers Squibb (2013) highlighted the rigorous procedural requirements and evidentiary burdens that must be met for a compulsory license to be granted. These cases illustrate that while the framework for compulsory licensing is designed to serve public interest, it simultaneously enforces strict criteria to prevent its misuse. The rejection of applications in these instances underlines the delicate balance that must be maintained: on one hand, ensuring that patent holders retain their rightful incentives to innovate, and on the other, protecting public health by preventing drug monopolies that render essential medicines inaccessible.

Furthermore, the study identifies significant challenges that accompany the implementation of compulsory licensing. These include concerns from the pharmaceutical industry regarding the potential negative impacts on innovation and foreign investment, as well as the risk of triggering international trade disputes. Critics argue that if compulsory licenses are granted too liberally, they could undermine the incentives for research and development (R&D) that drive the pharmaceutical industry. However, the paper contends that such risks must be weighed against the humanitarian imperative to make life-saving drugs accessible to all, especially in a developing country like India where a large segment of the population remains economically disadvantaged.

To address these multifaceted challenges, the paper has put forward a series of policy recommendations. These include strengthening public health safeguards by proactively issuing compulsory licenses for drugs addressing life-threatening diseases, encouraging local manufacturing to boost the production of affordable generics, and enhancing international collaboration to build a robust defense of these measures on the global stage. Additionally, the establishment of a transparent licensing framework with clear procedural guidelines and the adoption of balanced pricing models—such as tiered pricing—can help reconcile the interests of patent holders with those of the public. Such measures would not only streamline the process of granting compulsory licenses but also mitigate concerns related to innovation and international trade.

In summary, India's proactive use of compulsory licensing reflects a nuanced approach to intellectual property rights—one that seeks to prioritize public health without completely disregarding the need for continued pharmaceutical innovation. As global healthcare challenges continue to evolve, the development of a balanced, efficient, and transparent compulsory licensing regime will be vital. India’s experience in this arena provides a compelling model for other developing nations, demonstrating that with carefully crafted policies, it is possible to ensure that the benefits of medical innovation are shared widely, thereby making essential medicines accessible to all segments of society.

References

1. The Patents Act, 1970 (as amended in 2005).

2. Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).

3. Doha Declaration on TRIPS and Public Health, 2001.

4. Natco Pharma Ltd. v. Bayer Corporation, (2012) IPAB 100.

5. Lee Pharma v. AstraZeneca, (2015) Controller General of Patents.

6. BDR Pharmaceuticals v. Bristol-Myers Squibb, (2013) Controller General of Patents.

7. Ministry of Commerce and Industry, Government of India – Patent Office Reports.

8. World Health Organization (WHO) reports on intellectual property and public health.

9. Indian Journal of Intellectual Property Law, 2023.

[1] Indian Patent Act, 1970: Government of India. (1970). The Indian Patents Act, 1970. Ministry of Law and Justice, India. https://www.indiacode.nic.in/

[2] World Trade Organisation (WTO). (2001). Doha Declaration on the TRIPS Agreement and Public Health. https://www.wto.org/

[3] Bayer vs. Natco Pharma Case: Indian Patent Office. (2012). Order of the Controller of Patents in the matter of Compulsory License on Nexavar. Patent No. IN 215758. https://ipindia.gov.in/

[4] Sell, S. K. (2003). Private Power, Public Law: The Globalization of Intellectual Property Rights. Cambridge University Press

[5] World Trade Organization (WTO). (2003). Paragraph 6 Decision - Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health. https://www.wto.org/.

Abbott, F. M. (2007). The WTO Medicines Decision: World Pharmaceutical Trade and the Protection of Public Health. American Journal of International Law, 101(1), 40-78.

[6] World Health Organization. Access to Essential Medicines: Innovation, Development, and Investment, 2010

[7] World Trade Organization. Doha Declaration on TRIPS and Public Health, 2001

[8] Government of India. Patents Act, 1970 (as amended in 2005)

[9] World Health Organization. Access to Essential Medicines: A Critical Global Challenge, 2008

[10] Indian Journal of Intellectual Property Law. Analysis of Compulsory Licensing Provisions in India, 2023

Article Information

COMPULSORY LICENSING OF PATENTS: A CASE STUDY OF THE INDIAN PHARMACEUTICAL INDUSTRY BY: SAKSHAM GUPTA

Authors: SAKSHAM GUPTA

Journal IJLRA
ISSN 2582-6433
Published 2025/03/10
Issue 7

Citation Download Paper Full Details Search on Google Search on Google Scholar

About Journal

International Journal for Legal Research and Analysis

Abbreviation IJLRA
ISSN 2582-6433
Access Open Access
License CC 4.0

All research articles published in International Journal for Legal Research and Analysis are open access and available to read, download and share, subject to proper citation of the original work.

Disclaimer: The opinions expressed in this publication are those of the authors and do not necessarily reflect the views of International Journal for Legal Research and Analysis.

Current Issue

Ethics and Policy

For Authors